ATE396722T1 - Kleine moleküle zur behandlung von endzündlichen erkrankungen - Google Patents
Kleine moleküle zur behandlung von endzündlichen erkrankungenInfo
- Publication number
- ATE396722T1 ATE396722T1 AT00950262T AT00950262T ATE396722T1 AT E396722 T1 ATE396722 T1 AT E396722T1 AT 00950262 T AT00950262 T AT 00950262T AT 00950262 T AT00950262 T AT 00950262T AT E396722 T1 ATE396722 T1 AT E396722T1
- Authority
- AT
- Austria
- Prior art keywords
- dichlorophenyl
- treatment
- dihydroindol
- bromobenzyl
- small molecules
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14489599P | 1999-07-21 | 1999-07-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE396722T1 true ATE396722T1 (de) | 2008-06-15 |
Family
ID=22510624
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT00950262T ATE396722T1 (de) | 1999-07-21 | 2000-06-28 | Kleine moleküle zur behandlung von endzündlichen erkrankungen |
Country Status (9)
Country | Link |
---|---|
US (1) | US6414153B1 (de) |
EP (1) | EP1399155B1 (de) |
JP (1) | JP3833532B2 (de) |
AT (1) | ATE396722T1 (de) |
CA (1) | CA2378369C (de) |
DE (1) | DE60039078D1 (de) |
ES (1) | ES2306665T3 (de) |
MX (1) | MXPA02000625A (de) |
WO (1) | WO2001006984A2 (de) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6110922A (en) | 1998-12-29 | 2000-08-29 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds |
US6878700B1 (en) | 1998-12-29 | 2005-04-12 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds |
US6492408B1 (en) * | 1999-07-21 | 2002-12-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Small molecules useful in the treatment of inflammatory disease |
EP1294704A1 (de) | 2000-06-29 | 2003-03-26 | Abbott Laboratories | Aryl-phenylheterocyclyl-sulfid-derivate und deren anwendung als zelladhäsionshemmende anti-inflammatorische und immunsuppressive mittel |
US6521619B2 (en) | 2000-06-29 | 2003-02-18 | Icos Corporation | Aryl phenylcyclopropyl sulfide derivatives and their use as cell adhesion inhibiting anti-inflammatory and immune suppressive agents |
CA2492035A1 (en) | 2002-07-11 | 2004-01-15 | Vicuron Pharmaceuticals, Inc. | N-hydroxyamide derivatives possessing antibacterial activity |
US6974815B2 (en) | 2002-10-11 | 2005-12-13 | Bristol-Myers Squibb Company | Hexahydro-benzimidazolone compounds useful as anti-inflammatory agents |
US7199125B2 (en) | 2003-10-02 | 2007-04-03 | Bristol-Myers Squibb Company | Spiro-cyclic compounds useful as anti-inflammatory agents |
TW200616634A (en) | 2004-10-01 | 2006-06-01 | Bristol Myers Squibb Co | Crystalline forms and process for preparing spiro-hydantoin compounds |
US7186727B2 (en) | 2004-12-14 | 2007-03-06 | Bristol-Myers Squibb Company | Pyridyl-substituted spiro-hydantoin compounds and use thereof |
MY144968A (en) * | 2005-04-11 | 2011-11-30 | Xenon Pharmaceuticals Inc | Spiro-oxindole compounds and their uses as therapeutic agents |
MY145694A (en) | 2005-04-11 | 2012-03-30 | Xenon Pharmaceuticals Inc | Spiroheterocyclic compounds and their uses as therapeutic agents |
AR053713A1 (es) * | 2005-04-20 | 2007-05-16 | Xenon Pharmaceuticals Inc | Compuestos heterociclicos y sus usos como agentes terapeuticos |
BRPI0719166A2 (pt) * | 2006-10-12 | 2014-06-03 | Xenon Pharmaceuticals Inc | Derivados de espiro-oxindol tricíclicos e seus usos como agentes terapêuticos |
JP5460324B2 (ja) * | 2006-10-12 | 2014-04-02 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | 治療剤としてのスピロ−オキシインドール化合物の使用 |
US20110294842A9 (en) * | 2006-10-12 | 2011-12-01 | Xenon Pharmaceuticals Inc. | Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain |
US8552205B2 (en) * | 2007-11-29 | 2013-10-08 | Boehringer Ingelheim International Gmbh | Derivatives of 6,7-dihydro-5H-imidazo[1,2-alpha]imidazole-3-carboxylic acid amides |
EP2350091B1 (de) * | 2008-10-17 | 2015-06-03 | Xenon Pharmaceuticals Inc. | Spiro-oxindol verbindungen und ihre verwendung als therapeutische wirkstoffe |
DK2350090T3 (en) * | 2008-10-17 | 2015-09-07 | Xenon Pharmaceuticals Inc | Spiro-oxindole compounds and their use as therapeutic agents |
DK2445909T3 (da) | 2009-06-02 | 2014-02-10 | Boehringer Ingelheim Int | Derivater af 6,7-dihydro-5h-imidazo [1,2-a] imidazol-3-carboxylsyre amider |
EP2445914B1 (de) | 2009-06-02 | 2015-07-22 | Boehringer Ingelheim International GmbH | DERIVATE VON 6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOL-3-CARBONSÄUREAMIDEN |
AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
WO2011047174A1 (en) | 2009-10-14 | 2011-04-21 | Xenon Pharmaceuticals Inc. | Synthetic methods for spiro-oxindole compounds |
WO2011047173A2 (en) * | 2009-10-14 | 2011-04-21 | Xenon Pharmaceuticals Inc. | Pharmaceutical compositions for oral administration |
US9504671B2 (en) | 2010-02-26 | 2016-11-29 | Xenon Pharmaceuticals Inc. | Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents |
CN105820103B (zh) | 2015-01-28 | 2020-11-03 | 北京韩美药品有限公司 | N-苯甲酸基取代的苯并吡咯啉-2-酮类衍生物及其用途 |
US9682033B2 (en) | 2015-02-05 | 2017-06-20 | Teva Pharmaceuticals International Gmbh | Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1154976A (en) * | 1967-02-21 | 1969-06-11 | Pfizer Ltd | N-Phenyl Indoline Derivatives |
FR2015493A1 (de) | 1968-08-12 | 1970-04-30 | Sumitomo Chemical Co | |
DK123717B (da) | 1968-11-25 | 1972-07-24 | Sumitomo Chemical Co | 3-(3',5'-Dihalogenphenyl)-imidazolidin-2,4-dionderivater med mirobicid virkning. |
FR2075356A5 (en) | 1970-01-12 | 1971-10-08 | Sumitomo Chemical Co | N-aryl cyclic imides preparation |
JPS5136332B1 (de) | 1970-12-09 | 1976-10-07 | ||
JPS5188631A (en) | 1975-01-31 | 1976-08-03 | Hiiryoyosatsukinzai oyobi sonoseizoho | |
EP0091596B1 (de) | 1982-04-08 | 1991-09-11 | Shell Internationale Researchmaatschappij B.V. | Neue Hydantoine, ihre Herstellung und Verwendung |
IE940525L (en) | 1988-05-25 | 1989-11-25 | Warner Lambert Co | Known and selected novel arylmethylenyl derivatives of¹thiazolidinones, imidazolidinones and oxazolidinones useful¹as antiallergy agents and antiinflammatory agents |
US5208250A (en) | 1988-05-25 | 1993-05-04 | Warner-Lambert Company | Known and selected novel arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and anti-inflammatory agents |
US5306822A (en) | 1988-05-25 | 1994-04-26 | Warner-Lambert Company | Arylmethylenyl derivatives of oxazolidinone |
US5182289A (en) * | 1988-06-14 | 1993-01-26 | Schering Corporation | Heterobicyclic compounds having antiinflammatory activity |
US4977270A (en) | 1988-12-01 | 1990-12-11 | Ici Americas Inc. | Substituted 2,4-dioxodiazolidines and -thiadiazolidines and their use as herbicides |
US4911748A (en) | 1988-12-22 | 1990-03-27 | Ici Americas Inc. | Herbicidal 5-substituted-3-phenyl-imidazolidine-2,4-diones |
EP0545478A1 (de) | 1991-12-03 | 1993-06-09 | MERCK SHARP & DOHME LTD. | Heterocyclische Verbindungen als Tachykininantagoniste |
TW521073B (en) | 1994-01-05 | 2003-02-21 | Hoechst Marion Roussel Inc | New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them |
US5854232A (en) * | 1994-04-29 | 1998-12-29 | Pfizer Inc. | Acyclic anc cyclic amides as neurotransmitter release enhancers |
DE69524598T2 (de) * | 1994-06-20 | 2002-07-11 | Takeda Chemical Industries, Ltd. | Kondensierte imidazolderivate, ihre herstellung und verwendung |
DK0966447T3 (da) | 1997-03-03 | 2003-06-23 | Boehringer Ingelheim Pharma | Anvendelige små molekyler til behandling af betændelsessygdomme |
EP1007033B1 (de) | 1997-08-28 | 2008-04-23 | Novartis AG | Lymphozyten funktion antigen-1 antagonisten |
CN1191063C (zh) | 1998-03-27 | 2005-03-02 | 基因技术股份有限公司 | 治疗cd11/cd18粘附受体所介导疾病的拮抗剂 |
-
2000
- 2000-06-28 EP EP00950262A patent/EP1399155B1/de not_active Expired - Lifetime
- 2000-06-28 US US09/605,584 patent/US6414153B1/en not_active Expired - Lifetime
- 2000-06-28 CA CA002378369A patent/CA2378369C/en not_active Expired - Fee Related
- 2000-06-28 DE DE60039078T patent/DE60039078D1/de not_active Expired - Fee Related
- 2000-06-28 MX MXPA02000625A patent/MXPA02000625A/es active IP Right Grant
- 2000-06-28 ES ES00950262T patent/ES2306665T3/es not_active Expired - Lifetime
- 2000-06-28 JP JP2001511876A patent/JP3833532B2/ja not_active Expired - Fee Related
- 2000-06-28 WO PCT/US2000/017802 patent/WO2001006984A2/en active Application Filing
- 2000-06-28 AT AT00950262T patent/ATE396722T1/de not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP1399155A4 (de) | 2004-12-15 |
EP1399155A2 (de) | 2004-03-24 |
CA2378369C (en) | 2007-10-02 |
JP2004505005A (ja) | 2004-02-19 |
JP3833532B2 (ja) | 2006-10-11 |
US6414153B1 (en) | 2002-07-02 |
WO2001006984A2 (en) | 2001-02-01 |
ES2306665T3 (es) | 2008-11-16 |
CA2378369A1 (en) | 2001-02-01 |
MXPA02000625A (es) | 2002-07-02 |
DE60039078D1 (de) | 2008-07-10 |
WO2001006984A3 (en) | 2003-12-31 |
EP1399155B1 (de) | 2008-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE396722T1 (de) | Kleine moleküle zur behandlung von endzündlichen erkrankungen | |
ATE230394T1 (de) | Indolderivate und deren verwendung zur behandlung von malignen und anderen, auf pathologischen zellproliferationen beruhenden erkrankungen | |
TR200001954T2 (tr) | Faktör XA'nın önleyicileri olarak indol türevleri. | |
CY1115117T1 (el) | Παραγωγα υποκατεστημενων οξαζολιδινονων και η χρηση τους ως αναστολεις παραγοντα χα | |
SE9103752D0 (sv) | New compounds | |
DE69925256D1 (de) | Trisubstituierte 1,3,5-triazine derivate zur behandlung von hiv infektionen | |
DE69521620D1 (de) | Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom | |
NO20000521D0 (no) | 1-(N-fenylaminoalkyl)-piperazin derivater substituert i posisjon 2 på fenylringen | |
ATE238792T1 (de) | Verwendung von makroliden zur behandlung von glaukom | |
FI964772A (fi) | (a)-annelloidut pyrrolijohdannaiset ja niiden käyttö farmasiassa | |
ATE357438T1 (de) | 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems | |
ATE275400T1 (de) | Verwendung von melatonin zur behandlung der androgenetischen und diffusen alopezie vom weiblichen typ | |
BRPI0417476A (pt) | derivados de indol hidroxietilamina tricìclica e seu uso no tratamento da doença de alzheimer | |
ATE302002T1 (de) | Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit | |
MX9700959A (es) | Derivados de becimidazol que tienen actividad dopaminergica. | |
ATE290857T1 (de) | Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen | |
ATE255094T1 (de) | Piperazinderivate zur behandlung der niedrigen harnwege | |
DE60131968D1 (de) | PYRANOÄ2,3-cÜIMIDAZOÄ1,2-aÜPYRIDIN-DERIVATE ZUR BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN | |
ATE464048T1 (de) | Behandlung von alzheimer-krankheit und verwandten zuständen | |
ATE519740T1 (de) | Tetrahydroindolderivate zur behandlung von alzheimer-krankheit | |
ATE319709T1 (de) | Indolderivate zur behandlung von depression und angstzuständen | |
ATE305785T1 (de) | Cd45 hemmer | |
DE60005526D1 (de) | Verwendung von 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine zur behandlung von erkrankungen des magen-darm-traktes | |
ATE382045T1 (de) | Indol-2-onderivate zur behandlung von erkrankungen des zentralen nervensystems, erkrankungen des magen-darm-trakts und herzkreislauferkankungen | |
ATE224388T1 (de) | Indolderivate zur behandlung von migräne |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1399155 Country of ref document: EP |
|
REN | Ceased due to non-payment of the annual fee |